<DOC>
	<DOC>NCT00469183</DOC>
	<brief_summary>Evaluate atrophogenic potential of long-term use of Tri-Luma Cream on facial Melasma through biopsy examination.</brief_summary>
	<brief_title>Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma</brief_title>
	<detailed_description>Same as above.</detailed_description>
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>Subjects must have a clinical diagnosis of moderate to severe melasma Subjects willing to undergo biopsy four times throughout the study, two biopsies at baseline (one in a melasma involved area and one in a noninvolved area). The third and fourth biopsies will be performed at 3 months and 6 months, respectively; in order to avoid variability in histopathological findings, Subjects must have substantial melasma involvement of the cheeks and be willing to have the same general site biopsied at the baseline, month 3 and month 6 visits. Subjects with diagnosis of dermal melasma Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.) Subjects who have used retinoids, steroids, and/or skin lightening products 4 weeks prior to study entry Subjects who show signs of Poikiloderma of Civatte (mandibular hyperpigmentation) Subjects with a history of hypertrophic scarring or a history of keloids Subjects who are unable to avoid the use of a class 1 steroid during their participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>